TORONTO, ONTARIO -- (Marketwire) -- 11/30/12 --

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern" or "Company") (TSX VENTURE:MKI), is pleased to report first quarter highlights and results of operations from the Company's 2013 financial year, to September 30, 2012.

HIGHLIGHTS FOR THE QUARTER:

--  Increased Visualize: Vascular(TM) customer base to a total of 46
    customers which provide services in a combined total of 272 sites. 
    
--  Processed 1,243 cases in the quarter. 
    
--  Completed the acquisition of Mytrak Health Systems Inc.'s Mobile
    Technology Business Unit ("mHealth division") in conjunction with a $1.8
    million financing. 

"The customer base for our vascular product line continues to grow. We are refining the installation and training to streamline our start up process for Visualize: Vascular(TM) customers. We have implemented a cloud based system for delivery of medical images and reports for our customers so we can begin to scale the solution as we anticipate increased scanning volume. This new delivery system will enable our customers to begin to increase their volumes as we transition many of them from pre-revenue test scanning to contracted primary workload cases," stated Jeff Collins, CEO of The Medipattern Corporation. "The company also introduced its wearable mobile health device, SMARTCOACH(TM), into its Visualize: Vascular(TM) customer base. The medical community appreciates the device's ability to highlight heart activity and monitor the intensity of physical activity. Zwanger-Pesiri Radiology is utilizing SMARTCOACH(TM) as a method to encourage all 600 of their employees to meet their individual wellness goals, emphasizing that the entire organization benefits when the team is in good health."

"A new case study shows that Visualize: Vascular(TM) improved the Physician's ability to better identify those patients at risk to stroke," Collins stated. "The paper was presented at the Annual Meeting of the Society of Radiologists in Ultrasound, a division of the American College of Radiology. The paper shows that Visualize's 3D rendering results have a greater than 99% correlation to Magnetic Resonance Angiography (MRA). Each case was run with the standard of care: Carotid Ultrasound and MRA, and then with Visualize. Angiography is the gold standard for determining vascular integrity. The study shows that the standard of care Carotid Ultrasound only agreed with MRA 75% of the time. Using Visualize's 3D with Carotid Ultrasound improved diagnostic accuracy to the same level as angiography, bringing the accuracy of angiography to ultrasound. Clinical results continue to strongly substantiate the benefits of our vascular product line."

Collins continues, "Medipattern is positioned well to continue growing its vascular product line and increase delivery of its mHealth division products through this channel."

Financial Highlights for Q1 Fiscal 2013:

--  Revenue totaled $100,743 for the three month period ended September 30,
    2012 (Q1 Fiscal 2013) versus $6,504 for Q1 Fiscal 2012. Of the $94,239
    increase, device and accessories sales from the new mHealth division
    accounted for $76,399, subscription fees for Visualize: Vascular(TM), B-
    CAD-FOR-LIFE(TM) and SMARTCOACH(TM) accounted for $14,344 and $10,000
    from the sale of B-CAD(r) licenses. Throughout Q1 2013 the Company
    continued to focus its core R&D resources and marketing expertise on
    meeting its iaHealth division deadlines for final commercialization of
    its Visualize: Vascular(TM) software, while improving the customer user
    experience and device interface on its mHealth division technology
    platform. As a consequence, no licensing or professional fees were
    earned in the quarter (Q1 2012 - $nil); 
    
--  Non-interest operating expenses in Q1 Fiscal 2013 totaled $1,291,287
    versus $581,029 for Q1 Fiscal 2012, an overall increase of 122%. Of the
    $710,258 increase, $403,492 was attributable to the addition of the new
    mHealth division, while related acquisition costs, increased patent fees
    and higher share-based compensation accounted for the balance of the
    increased expenses. The Company remains committed to controlling all
    discretionary non-interest spending until operating cash flow improves
    and new financing is arranged; 
    
--  Total interest expense (including accreted interest on Convertible Debt)
    for Q1 Fiscal 2013 increased 68% to $201,279 (Q1 2012 - $120,097) as a
    result of the commencement of 8% interest due on certain Convertible
    Notes starting on January 1, 2012; 
    
--  In Q1 Fiscal 2013 the Company also recorded 2 significant non-cash
    items; one, a fair value gain on embedded conversion options in its 2010
    Convertible Notes of $619,765 (Q1 - 2012 - $39,287) and two, a goodwill
    impairment provision on its recently acquired mHealth division of
    $1,764,584; 
    
--  Resulting net loss for Q1 Fiscal 2013 was $2,549,663 ($0.03 per share)
    versus $653,096 ($0.01 per share) for Q1 fiscal 2012; 
    
--  As at September 30, 2012, cash totaled $238,733 (June 30, 2012 -
    $348,732), current assets, including short-term investments of $272,689
    (June 30, 2012 - $271,665), were $1,549,431 (June 30, 2012 - $870,989)
    and current liabilities were $1,050,475 (June 30, 2012 - $355,636).
    Working capital at September 30, 2012 totaled $498,956 (June 30, 2012 -
    $515,353), total assets totaled $3,108,838 (June 30, 2012 - $922,373)
    and total liabilities were $6,814,934 (June 30, 2012 - $6,652,560).

Subsequent to September 30, 2012

--  The Company initiated significant cost reduction initiatives to minimize
    monthly cash expenses and allow available financial resources to focus
    specifically on revenue generation. Included in these cash containment
    measures is senior management's (including its NEO's) agreement to
    receive no or reduced salaries until sufficient new liquidity is
    achieved through either new capital financing or enhanced revenue
    generation. 
    
--  November 7, 2012, the Company announced it had arranged a term debt
    facility ('Facility") to provide up to $1,000,000 of working capital.
    The Facility calls for advances to be made monthly to the Company,
    initially for $100,000. The Notes will expire on June 30, 2013, and will
    bear interest at 6% per annum. The Notes will be secured by a general
    security agreement over all the assets of the Company, in priority to
    all existing security interests granted by the Company. The closing of
    the Facility and the initial $100,000 advance is subject to completion
    of definitive agreements and TSX Venture Exchange approval. Medipattern
    and its Board have agreed the holders of the Notes have the right to
    appoint up to two representatives as directors of Medipattern's Board.
    To date, this Facility has not closed and no funds have been advanced. 
    

                                                                            
                         THE MEDIPATTERN CORPORATION                        
                                                                            
     UNAUDITED CONDENSED STATEMENT OF OPERATIONS and COMPREHENSIVE LOSS     
           FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2012 AND 2011           
                                                                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                 Three Months  Three Months 
                                                        Ended         Ended 
                                                    September     September 
                                                          30,           30, 
                                                         2012          2011 
                                                 ---------------------------
                                                 ---------------------------
Revenues                                                                    
  Devices and accessories                         $    76,399   $         - 
  Licensing fees                                       10,000             - 
  Professional fees                                         -             - 
  Subscription rental fees                             14,344         6,504 
                                                 ------------- -------------
                                                      100,743         6,504 
                                                 ------------- -------------
Expenses                                                                    
  Cost of Sales                                        70,549             - 
  Research and development                            331,273       260,530 
  Administration and product support                  752,935       209,910 
  Sales and marketing                                 136,530       110,589 
  Interest on convertible debt                        117,547        49,943 
  Accretion of interest on convertible debt            83,732        70,154 
  Unrealized gain on convertible debt conversion                            
   option                                            (619,765)      (39,287)
  Goodwill impairment provision                     1,764,584             - 
  Foreign exchange loss (gain)                          6,488          (271)
  Investment income                                    (2,165)       (9,762)
  Depreciation of property and equipment                8,697         7,794 
                                                 ------------- -------------
                                                    2,650,406       659,600 
                                                 ------------- -------------
                                                                            
Net loss and total comprehensive loss             $(2,549,663)  $  (653,096)
                                                 ------------- -------------
                                                 ------------- -------------
                                                                            
Loss per share - basic and diluted                $     (0.03)  $     (0.01)
                                                 ------------- -------------
                                                 ------------- -------------
                                                                            
Weighted average number of common shares                                    
outstanding                                        75,286,469    57,404,579 
                                                 ------------- -------------
                                                 ------------- -------------

About the Medipattern Corporation:

Medipattern(r) is the award-winning leader in the development and commercialization of healthcare solutions that positively impact people's lives through the prevention of disease and analysis of medical images and data. Medipattern's Knowledge-based Informatics (MKI) platform enables delivery of these streamlined solutions. Medipattern mHealth uses patented prevention technologies to engage, coach and monitor people in achieving their personalized goals. Medipattern iaHealth uses patented pattern recognition technology to analyze medical data to aid medical practitioners in the assessment of disease and critical anatomy. For more information, please visit the Company's website: www.medipattern.com.

Medipattern(r) and B-CAD(r) are registered marks of The Medipattern Corporation. Visualize:Vascular(TM) is a trademark of the Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates'', "believes'', "estimates'', "expects'', "plans'', "intends'', "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.